Literature DB >> 22608002

RCDB: Renal Cancer Gene Database.

Jayashree Ramana1.   

Abstract

BACKGROUND: Renal cell carcinoma or RCC is one of the common and most lethal urological cancers, with 40% of the patients succumbing to death because of metastatic progression of the disease. Treatment of metastatic RCC remains highly challenging because of its resistance to chemotherapy as well as radiotherapy, besides surgical resection. Whereas RCC comprises tumors with differing histological types, clear cell RCC remains the most common. A major problem in the clinical management of patients presenting with localized ccRCC is the inability to determine tumor aggressiveness and accurately predict the risk of metastasis following surgery. As a measure to improve the diagnosis and prognosis of RCC, researchers have identified several molecular markers through a number of techniques. However the wealth of information available is scattered in literature and not easily amenable to data-mining. To reduce this gap, this work describes a comprehensive repository called Renal Cancer Gene Database, as an integrated gateway to study renal cancer related data.
FINDINGS: Renal Cancer Gene Database is a manually curated compendium of 240 protein-coding and 269 miRNA genes contributing to the etiology and pathogenesis of various forms of renal cell carcinomas. The protein coding genes have been classified according to the kind of gene alteration observed in RCC. RCDB also includes the miRNAsdysregulated in RCC, along with the corresponding information regarding the type of RCC and/or metastatic or prognostic significance. While some of the miRNA genes showed an association with other types of cancers few were unique to RCC. Users can query the database using keywords, category and chromosomal location of the genes. The knowledgebase can be freely accessed via a user-friendly web interface at http://www.juit.ac.in/attachments/jsr/rcdb/homenew.html.
CONCLUSIONS: It is hoped that this database would serve as a useful complement to the existing public resources and as a good starting point for researchers and physicians interested in RCC genetics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608002      PMCID: PMC3438103          DOI: 10.1186/1756-0500-5-246

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Findings

Background

Renal cell carcinoma (RCC) represents a heterogeneous group of tumors differing in genetic background, responses to surgical and medical therapy and prognoses. It accounts for 3% of adult malignancy and results in over 100000 deaths worldwide annually [1]. It is the one of the leading causes of cancer deaths in Western countries with steadily escalating incidence over the last few decades [2]. RCC is classified based on morphological and genetic differences. This classification distinguishes metanephric adenoma oncocytoma and papillary adenoma as benign tumors from the clear cell (ccRCC), papillary/chromophilic, chromophobic (chRCC) and collecting duct RCC. This classification is important because of its prognostic implications. ccRCC is the most common and accounts for 70% of RCCs. RCC is diagnosed through imaging studies including CT and ultrasound, but kidney biopsy is an invasive technique that might result in complications and would not provide accurate diagnosis in certain situations. For early presentations, surgical extirpation through nephrectomy provides an effective treatment, but patients usually present at advanced stages, leading to poor outcomes. Even for patients without metastatic spread who undergo nephrectomy, metastatic recurrence is frequent. Apart from surgery, RCC is resistant to chemotherapy and radiotherapy. Cytokine therapy, which is reserved for patients with advanced disease, can produce partial responses in 10%–15% and durable remissions in 5% of the patients. The therapeutic approach to RCC is determined by the probability of cure, which is related directly to the stage or degree of tumor dissemination. An accurate assessment of the individual risk of disease progression and mortality after treatment is crucial to counsel patients and plan individualized surveillance protocols. Multiple studies have investigated the deregulation of genes in renal carcinogenesis at the genomic, transcriptomic as well as proteomic levels using a suite of molecular profiling techniques [3]. These include cytogenetic studies [4], gene expression analyses through tissue microarrays [5,6], serum proteomics [7], genomic resequencing [8], and microRNA profiling [9] and have yielded useful insights into RCC biology and clinical presentation, and have led to a rich understanding of the heterogeneity of this disease which greatly influences prognostic decisions. Despite the voluminous data available on RCC, the information is rather sporadic and scattered in literature. In the last few years, a number of databases have emerged with a central focus on a particular cancer type as exemplified by Lung Cancer Database [10], Oral Cancer Database [11], Breast Cancer Gene Database [12], Cervical Cancer Database [13] etc., however there is no report of any such database for RCC. This work describes the development of the Renal Cancer Gene Database (RCDB) that catalogs the protein-coding and miRNA genes known to be involved in renal carcinogenesis as evidenced by biomedical literature. Due to its specific focus on RCC, unlike dbDEMC [14] and miR2Disease [15], it provides a far broader coverage of the miRNAsdysregulated in RCC. It incorporates information regarding the relevance of miRNAs to molecular classification of renal tumors (neoplasms) based on tumor type, metastatic status or prognosis group. This provides an additional advantage over other databases like miR2disease. Many of the protein-coding and miRNA genes in RCDB are useful prognostic and diagnostic markers and are therefore clinically relevant. These may also serve as therapeutic targets.

Construction and content

RCDB contains information on RCC-implicated genes compiled from research articles indexed in PubMed. The PubMed database was queried with different keywords like renal cell carcinoma, renal cancer or tumor etc. and the articles retrieved were manually scrutinized to winnow the genes affecting the etiology of RCC. The final lists of 240 protein-coding and 269 miRNA genes were identified in this way and used to populate the database. The former were grouped into following six categories (Table 1) based on the kind of gene alteration observed in RCC: 1) (silencing/downregulation through) Methylation, 2) Overexpression, 3) Downregulation, 4) Mutation and 5) Translocation and 6) Unclassified. The latter (miRNAs) were categorized according to their differential expression in the different types of RCC. This classification scheme (Table 2) includes differential expression in: 1) chromocytoma vs oncocytoma 2) ccRCC vs papillary RCC 3) Poor vs Good prognosis 4) ccRCC vs normal kidney 5) chRCC vs normal kidney 6) ccRCC vs chRCC 7) Metastatic vs Non-metastatic RCC 8) Primary vs Late metastasis. There exist few overlaps of miRNAs within these categories. RCDB is implemented as a MySQL database and the web-interface built in PHP.
Table 1

Classification of protein-coding genes in RCDB

CategoryNo. of genes
Methylation
26
Overexpression
112
Downregulation
51
Mutation
24
Translocation
8
Unclassified17
Table 2

Classification of miRNA genes in RCDB

CategoryNo. of miRNAs
1) chromocytoma vs oncocytoma
35
2) ccRCC vs papillary RCC
56
3) Poor vs Good prognosis
18
4) ccRCC vs normal kidney
190
5) chRCC vs normal kidney
57
6) ccRCC vs chRCC
64
7) Metastatic vs Non-metastatic RCC
33
8) Primary vs Late metastasis11
Classification of protein-coding genes in RCDB Classification of miRNA genes in RCDB

Utility and discussion

The web interface query form allows users to query the protein coding genes from database using keyword, the class and the chromosome number (Figure 1a). This retrieves a list of genes (Figure 1b) where each gene entry is further linked (Figure 1c) to its specific details comprising its gene, nucleotide and protein accession numbers, its chromosomal location as well as its involvement in RCC and the PubMed records corroborating the same. The miRNAs can also be browsed in a similar way. The miRNA entries are linked to miRBase [16] wherever available. The ViroBLAST [17] tool searches a user-defined query sequence against the sequences available in the database. This offers the additional advantage of parsing the results according to E-value or score chosen by the user.
Figure 1

Illustration of RCDB. (a) The web interface for data query and retrieval. (b) The query form retrieves the list of genes as required by the query. (c) Each gene in the list is linked to its specific details.

Illustration of RCDB. (a) The web interface for data query and retrieval. (b) The query form retrieves the list of genes as required by the query. (c) Each gene in the list is linked to its specific details. RCDB provides a comprehensive compilation of information obtained from published RCC research, complemented with the information from public databases like Swissprot, Refseq etc. It would allow the users in performing comparative studies, e.g. to deduce the genes that are shared with other cancers as well as the ones which are unique to RCC. This analysis was performed for miRNA genes in RCDB by surveying the literature for the involvement of these miRNAs in different cancers (Additional file 1). While most of the miRNAs were found to be reported in other types of malignancies, few were unique to RCC. The latter included miR455, miR219, miR509, miR627, miR648, miR510, miR379, miR136, miR376b, miR154, miR551b, miR514, miR383, miR453, miR582, miR450, miR425, miR365-1 etc.

Conclusion

RCDB has been developed as an integrated information source to assist the research efforts of scientists and clinicians working on renal carcinoma. Besides providing a panoramic overview of RCC, it facilitates thorough exposition of each gene by providing hyperlinks to relevant PubMed records. In future, RCDB would be updated and additional data incorporated. It is anticipated that RCDB would serve as a valuable resource to the scientific community.

Availability and requirements

Project home page: http://www.juit.ac.in/attachments/jsr/rcdb/homenew.html.

Competing interests

The author declares that she has no competing interests.

Author’s contributions

JR conceptualized the study, developed the database and wrote the manuscript.

Additional file 1:

A comparison of miRNAs common and unique to RCC and other cancers. Click here for file
  17 in total

1.  The breast cancer gene database: a collaborative information resource.

Authors:  R A Baasiri; S R Glasser; D L Steffen; D A Wheeler
Journal:  Oncogene       Date:  1999-12-23       Impact factor: 9.867

2.  MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens.

Authors:  Lihong Weng; Xiwei Wu; Hanlin Gao; Bing Mu; Xuejun Li; Jin-Hui Wang; Chao Guo; Jennifer M Jin; Zhuo Chen; Maricela Covarrubias; Yate-Ching Yuan; Lawrence M Weiss; Huiqing Wu
Journal:  J Pathol       Date:  2010-09       Impact factor: 7.996

3.  OrCGDB: a database of genes involved in oral cancer.

Authors:  A E Levine; D L Steffen
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

4.  Pathway signature and cellular differentiation in clear cell renal cell carcinoma.

Authors:  Han W Tun; Laura A Marlow; Christina A von Roemeling; Simon J Cooper; Pamela Kreinest; Kevin Wu; Bruce A Luxon; Mala Sinha; Panos Z Anastasiadis; John A Copland
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

5.  Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment.

Authors:  Trisha S Tavares; David Nanus; Ximing J Yang; Lorraine J Gudas
Journal:  Cancer Biol Ther       Date:  2008-10-09       Impact factor: 4.742

6.  CCDB: a curated database of genes involved in cervix cancer.

Authors:  Subhash M Agarwal; Dhwani Raghav; Harinder Singh; G P S Raghava
Journal:  Nucleic Acids Res       Date:  2010-11-02       Impact factor: 16.971

7.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

Authors:  Gillian L Dalgliesh; Kyle Furge; Chris Greenman; Lina Chen; Graham Bignell; Adam Butler; Helen Davies; Sarah Edkins; Claire Hardy; Calli Latimer; Jon Teague; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Simon Forbes; Mingming Jia; David Jones; Henry Knott; Chai Yin Kok; King Wai Lau; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maguire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Sarah O'Meara; Erin Pleasance; Arjunan Rajasingham; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Kelly Turrell; Karl J Dykema; Sok Kean Khoo; David Petillo; Bill Wondergem; John Anema; Richard J Kahnoski; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2010-01-06       Impact factor: 49.962

8.  HLungDB: an integrated database of human lung cancer research.

Authors:  Lishan Wang; Yuanyuan Xiong; Yihua Sun; Zhaoyuan Fang; Li Li; Hongbin Ji; Tieliu Shi
Journal:  Nucleic Acids Res       Date:  2009-11-09       Impact factor: 16.971

Review 9.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

10.  miR2Disease: a manually curated database for microRNA deregulation in human disease.

Authors:  Qinghua Jiang; Yadong Wang; Yangyang Hao; Liran Juan; Mingxiang Teng; Xinjun Zhang; Meimei Li; Guohua Wang; Yunlong Liu
Journal:  Nucleic Acids Res       Date:  2008-10-15       Impact factor: 16.971

View more
  24 in total

1.  FOXM1-Activated LINC01094 Promotes Clear Cell Renal Cell Carcinoma Development via MicroRNA 224-5p/CHSY1.

Authors:  Yufeng Jiang; Haimin Zhang; Wei Li; Yang Yan; Xudong Yao; Wenyu Gu
Journal:  Mol Cell Biol       Date:  2020-01-16       Impact factor: 4.272

Review 2.  Potential biofluid markers and treatment targets for renal cell carcinoma.

Authors:  Hiromi I Wettersten; Robert H Weiss
Journal:  Nat Rev Urol       Date:  2013-04-02       Impact factor: 14.432

3.  LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.

Authors:  Wei Zhai; Yin Sun; Changcheng Guo; Guanghui Hu; Mingchao Wang; Jiayi Zheng; WanYing Lin; Qingbo Huang; Gonghui Li; Junhua Zheng; Chawnshang Chang
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

4.  DiPhiSeq: robust comparison of expression levels on RNA-Seq data with large sample sizes.

Authors:  Jun Li; Alicia T Lamere
Journal:  Bioinformatics       Date:  2019-07-01       Impact factor: 6.937

5.  Web-based tools for microRNAs involved in human cancer.

Authors:  Fermín Mar-Aguilar; Cristina Rodríguez-Padilla; Diana Reséndez-Pérez
Journal:  Oncol Lett       Date:  2016-04-18       Impact factor: 2.967

6.  MGDB: a comprehensive database of genes involved in melanoma.

Authors:  Di Zhang; Rongrong Zhu; Hanqian Zhang; Chun-Hou Zheng; Junfeng Xia
Journal:  Database (Oxford)       Date:  2015-09-30       Impact factor: 3.451

Review 7.  Prediction of MicroRNA Precursors Using Parsimonious Feature Sets.

Authors:  Petra Stepanowsky; Eric Levy; Jihoon Kim; Xiaoqian Jiang; Lucila Ohno-Machado
Journal:  Cancer Inform       Date:  2014-10-14

Review 8.  Human cancer databases (review).

Authors:  Athanasia Pavlopoulou; Demetrios A Spandidos; Ioannis Michalopoulos
Journal:  Oncol Rep       Date:  2014-10-31       Impact factor: 3.906

9.  Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1).

Authors:  W Li; M Liu; Y Feng; Y-F Xu; Y-F Huang; J-P Che; G-C Wang; X-D Yao; J-H Zheng
Journal:  Br J Cancer       Date:  2014-07-10       Impact factor: 7.640

10.  Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.

Authors:  Clizia Chinello; Marta Cazzaniga; Gabriele De Sio; Andrew James Smith; Erica Gianazza; Angelica Grasso; Francesco Rocco; Stefano Signorini; Marco Grasso; Silvano Bosari; Italo Zoppis; Mohammed Dakna; Yuri E M van der Burgt; Giancarlo Mauri; Fulvio Magni
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.